EUCTR2007-000710-37-IT进行中（未招募）不适用
A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN) - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •· Males and females age > 18 years · Patients with documented clinical diagnosis and electrophysiological evidence of MMN · Patients who previously responded to IVIG and are on stable tratment with IVIG for at least 12 weeks prior screening · Patients trated with the equivalent of >=0.4 g/kg body weight (bw) IVIG per month · Women of childbearing potential must use a medically approved method of contraceprion and must have a negative urine pregnancy test at screening · provision of informed consent by patient
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •· ASAT or ALAT concentration > 2.5 times the UNL · creatinine concentration > 1.5 times the UNL · known allergic reactions to blood products · any skin disease interfering with the assessment of injection site reactions · any other medical condition, which in the opinion of the investigator may interfere with successful completion of the protocol · any condition likely to interfere with the evaluation of the study drug or satisfactory conduct of the trial · participation in a study with an investigational drug within three months prior to enrolment · patients treated with the equivalent of > 2.0 g/kg bw IVIG per month
研究者
相似试验
进行中（未招募）
不适用
A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN)EUCTR2007-000710-37-DECSL Behring AG10
进行中（未招募）
1 期
A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN)Patients with multifocal motor neuropathy, who are treated successful with IVIG and had a stable IVIG treatment schedule for at least 12 weeks prior to screening.MedDRA version: 9.1 Level: LLT Classification code 10065579 Term: Multifocal motor neuropathyEUCTR2007-000710-37-GBCSL Behring AG10
进行中（未招募）
不适用
Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dactylis glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca elatior, Secale cereale) in patients with allergic rhinoconjunctivitis sensitized to grass and with or without rye pollen sensitization. A prospective, double-blind, randomized, placebo-controlled, multi-centre trial. - Specific Immunotherapy with CLUSTOID®: Efficacy and safetyThis clinical trial will evaluate the benefit of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® over placebo in patients with allergic rhinoconjunctivits.EUCTR2008-000513-29-DEROXALL Medizin GmbH
已完成
不适用
Intravenous versus subcutaneous immunoglobulin therapy in multifocal motor neuropathyMotor neuron diseaseISRCTN66618743Academic Medical Centre (AMC) (The Netherlands)10
尚未招募
4 期
Intravenous versus Subcutaneous Immunoglobuline therapy in Multifocal motor neuropathymotor neuropathynerve damage10034606NL-OMON31197Academisch Medisch Centrum10